JDS THERAPEUTICS LAUNCHES WEBSITE FOR ZERAMAX™

JDS THERAPEUTICS LAUNCHES WEBSITE FOR ZERAMAX™

www.zeramax.com will provide patients with type 2 diabetes and healthcare professionals with product and purchasing information

PURCHASE, NY, June 10, 2013  – JDS Therapeutics, LLC, a marketer of proprietary, high-quality healthcare products to physicians, healthcare-delivery networks, and other healthcare professionals, announced today the launch of its new website, www.zeramax.com, in support of the launch of Zeramax™, a unique, patented once-daily medical food for the dietary management of type 2 diabetes.

The new website will provide product-specific, disease state, and ordering information about Zeramax™, the first product to be launched by JDS Therapeutics. It will also have Patient and Healthcare Professional tabs so that visitors can access product information most relevant to their needs and interests.  Additional features of the website include a Mechanism of Action (MOA) video and Frequently Asked Questions (FAQs).

President and CEO Michael Satow commented, “We are very excited about the launch of our website for Zeramax™, and we are confident that the website will provide both healthcare professionals and their patients with useful information about Zeramax™ and type 2 diabetes that will allow them both to make the best treatment decisions possible for the benefit of their patients and themselves.”  Mr. Satow added “JDS Therapeutics strongly believes that Zeramax™ can play an important role in the dietary management of patients with type 2 diabetes.”

About JDS Therapeutics
JDS Therapeutics markets proprietary, high-quality healthcare products to physicians, healthcare-delivery networks, and other healthcare professionals. JDS is focused on providing patients with scientifically backed, natural approaches to meeting their healthcare needs. JDS Therapeutics owns more than 100 issued patents worldwide involving clinically active natural compounds. JDS was founded in 2011, by Phillip and Michael Satow, a father and son team whose previous company, JDS Pharmaceuticals was sold in 2007 to Noven Pharmaceuticals for $125 million.

For more information, please contact us.